Despite the stock market volatility of recent weeks, private investors' risk appetite does not seem to have wavered in the United States, and the dip is being bought by the truckload. Has the risk appetite of young investors changed permanently?
U.S. President Donald Trump is pressuring Federal Reserve Chairman Jay Powell to cut interest rates, even though the Fed is, by law, an independent entity free from political influence. Next year, Trump will get to appoint a new Fed chair when Powell's term ends. A central bank under the president’s thumb would not restore the market’s waning confidence in U.S. politics. One might ask: Is the U.S. “on the road to Zimbabwe”?
The return of an investment portfolio relative to an index is a simple but brutally honest measure of stock picking success. A similar measure, we believe, will also serve as a tool for assessing the quality and independence of equity research.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Do you know how to code and are you interested in investing or information democratizing? Join our team to develop the platform, which is used by over 70,000 active investors.
Sampo Group sustained strong top-line growth and delivered robust underwriting profit growth in 2024, supported by solid development in all business areas.
Double materiality assessment is a tricky term, but in practice it is the point in sustainability reporting where the most relevant issues for the stock picker should be identified.
CSRD reports, or sustainability reports, will be part of mandatory annual reporting in the future. The reporting as a whole is very complex, and the aim of this new series of articles is to explain the key aspects of CSRD reporting for stock pickers.
The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.
Sampo Group’s top line growth remained strong and underlying trends positive in January-September 2024, driving underwriting profit growth in a mixed claims environment.
The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.
Buy low and sell high is the most overused phrase in the investment world. Theoretically, a strategy based on this phrase is probably one of the best investment strategies in hindsight, but often the cheap or expensive nature of a stock or investment can only be determined after the fact.
We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.
The Finnish protein production revolutioniser Solar Foods Oyj (hereinafter “Solar Foods” or “the Company”) is planning a listing and application for admission of shares to trading on the Nasdaq First North Growth Market Finland marketplace maintained by Nasdaq Helsinki Ltd. The planned listing would be carried out in September as a technical listing, i.e. no share issue or sale will be arranged in connection with it.
On 17 June 2024, Sampo and Topdanmark entered into a combination agreement. In this IR blog entry, Sampo address questions shareholders might ask regarding the offer at this point.
The point of stock picking is to get better returns than from index funds. If stock picking does not deliver excess returns, the investor always has the option of capturing index returns with a low-cost index fund. As the tech giants have continued their strong rise, their relative weight in equity indices has increased. When a smaller group of stocks drives the index up faster than the rest of the group, it means that more investors are missing out on index returns. Stock picking has worked well in recent years, if it has focused primarily on the largest companies. This may not continue forever, but there are good reasons for this trend.
As fellow investors will have noticed, Nasdaq Helsinki hasn't seen many new listings for a couple of years. The IPO boom of 2021-22 has been followed by a post-bubble hangover. However, investors can expect further IPOs within a year, unless the economy falters again.
Stock markets around the world are hitting new highs, but for those investing in small companies, the last few years have not been easy. Large companies have dominated the top of the returns lists. It is generally believed that smaller companies, while riskier, can deliver better returns over time because they have more room to grow. But this is not always, if ever, the case.
What if China invaded Taiwan? A war would probably lead to a global economic collapse worse than the financial crisis, and there would be no point in owning stocks.
